证券代码：002644 证券简称：佛慈制药 公告编号：2025-019 3.公司近期经营情况正常，内外部经营环境未发生重大变化。 兰州佛慈制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 兰州佛慈制药股份有限公司（以下简称"公司"）股票（证券简称：佛慈制药， 证券代码：002644）连续 2 个交易日内（2025 年 7 月 29 日、7 月 30 日）收盘价 格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规则》的有关规定，属 于股票交易异常波动的情况。 二、公司关注、核实情况说明 针对公司股票异常波动，公司董事会对有关事项进行了核实，现就有关情况 说明如下： 1.公司前期披露的信息不存在需要更正、补充之处。 2.公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息。 3.公司郑重提醒广大投资者：《证券时报》《证券日报》和巨潮资讯网 （www.cninfo.com.cn）为公司选定的信息披露媒体，公司所有信息均以在上述媒 体披露的信息为准，敬请广大 ...

一、行情回顾 沪指全天冲高回落，创业板指盘中跌超2%。影视股延续强势，幸福蓝海、金逸影视等涨停。婴童概念股拉升，阳光乳业、安正时尚等封板。医药股冲高回 落，辰欣药业、佛慈制药等涨停。下跌方面，高位人气股集体大跌，东信和平、拓山重工等跌停。个股跌多涨少，沪深京三市超3500股飘绿，今日成交1.87 万亿。 二、当日热点 1.影视 影视板块今日再度大涨，幸福蓝海继续20cm涨停、天府文旅、金逸影视等涨停。 据猫眼专业版数据，截至7月30日，《南京照相馆》票房累计6.96亿，猫眼预测最终票房达37.52亿。 中银证券表示，当下医药板块，一方面政策端的态度正在逐步转向，集采规则逐步优化；另一方面，医药板块经过几年的研发投入，再研管线逐步进入收获 期，并且近期医药行业海外BD的趋势正在加速，这也进一步体现出当下我国创新药在全球的竞争力，医药行业正逐步走出低谷，伴随后续政策面以及企业 盈利面的逐步改善，医药板块有望迎来估值重塑的机会。 3.优化生育 | 股票名称 | | 最新价 = | 涨跌幅 = | 涨停时间 ◆ | 换手率 = | 流通市值 = | | | --- | --- | --- | --- | --- | ...

Group 1 - The stock of Foci Pharmaceutical has hit the daily limit up for three consecutive trading days, with a current price of 11.76 yuan and a turnover rate of 17.08% [2] - During the consecutive limit-up period, the stock has increased by 33.03% with a cumulative turnover rate of 38.35% [2] - The latest total market capitalization of the company in the A-share market is 60.05 billion yuan [2] Group 2 - The company's Q1 report shows total operating revenue of 216 million yuan, a year-on-year decrease of 21.22%, while net profit reached 19 million yuan, a year-on-year increase of 5.41% [2] - Recent trading data indicates significant fluctuations in daily stock performance, with notable net inflows of main funds on specific days [2]

Market Overview - The Chinese medicine sector rose by 1.0% on July 29, with Foci Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3609.71, up 0.33%, while the Shenzhen Component Index closed at 11289.41, up 0.64% [1] Top Gainers in Chinese Medicine Sector - Foci Pharmaceutical (002644) closed at 10.69, up 9.98% with a trading volume of 841,300 shares and a turnover of 876 million yuan [1] - Zhongsheng Pharmaceutical (002317) also rose by 9.98% to 19.73, with a trading volume of 1,168,400 shares and a turnover of 2.26 billion yuan [1] - Other notable gainers include: - Zhendong Pharmaceutical (300158) up 6.66% to 7.69 [1] - Huasen Pharmaceutical (002907) up 6.50% to 18.51 [1] - Kangjia Pharmaceutical (600557) up 5.61% to 16.58 [1] Top Losers in Chinese Medicine Sector - Qidi Pharmaceutical (000590) fell by 2.65% to 12.13, with a trading volume of 134,500 shares and a turnover of 163 million yuan [2] - Zhenbaodao (603567) decreased by 2.21% to 12.40, with a trading volume of 182,700 shares and a turnover of 227 million yuan [2] - Other notable losers include: - Yunnan Baiyao (000538) down 1.20% to 55.82 [2] - Kangmei Pharmaceutical (600518) down 0.94% to 2.10 [2] Capital Flow Analysis - The Chinese medicine sector saw a net inflow of 798 million yuan from institutional investors, while retail investors experienced a net outflow of 625 million yuan [2][3] - Notable net inflows from institutional investors include: - Zhongsheng Pharmaceutical (002317) with a net inflow of 308 million yuan [3] - Zhendong Pharmaceutical (300158) with a net inflow of 96.32 million yuan [3] - Conversely, significant net outflows from retail investors were observed in: - Zhongsheng Pharmaceutical (002317) with a net outflow of 98.88 million yuan [3] - Zhendong Pharmaceutical (300158) with a net outflow of 65.62 million yuan [3]

三胎概念板块集体高开，贝因美（002570）、阳光乳业（001318）、佛慈制药（002644）、诺邦股份 （603238）、爱婴室（603214）涨停，骑士乳业涨超15%，西部牧业（300106）、太湖雪、孩子王 （301078）涨超10%，延江股份（300658）、汉商集团（600774）、熊猫乳品（300898）、嘉必优、戴 维医疗（300314）跟涨。消息面上，国家育儿补贴方案于昨日公布。育儿补贴制度从2025年1月1日起， 对符合法律法规规定生育的3周岁以下婴幼儿发放补贴，育儿补贴按年发放，现阶段国家基础标准为每 孩每年3600元，发放补贴至婴幼儿年满3周岁。 ...

Industry Overview - The beverage market in 2024 shows significant growth with a 7.8% increase in overall sales, driven by health-oriented drinks like sugar-free tea and functional beverages, which grew by 16.6% and 12.1% respectively, with sugar-free tea experiencing a remarkable 60% growth [2] - The sugar-free tea market is becoming increasingly concentrated, with Nongfu Spring holding over 70% market share, while electrolyte drinks are emerging as a new growth point, led by brands like Yuanqi Forest [2] - The trend towards health and taste is expected to drive competition in the beverage market, focusing on efficiency and differentiation [2] Tropical Fruit Trends - Guava has emerged as a popular ingredient in the beverage industry, with brands like Heytea and Shuyi Shao Xian Cao launching new guava products, reflecting its high aesthetic appeal and health benefits [3][4] - The rise of guava is attributed to its vibrant color, high vitamin C content, and low calories, making it versatile for innovation [3] Functional Foods and Health Trends - The functional food industry, particularly traditional Chinese medicine-based products, is evolving from simple cultivation to a complete industrial chain, benefiting from health consumption upgrades and policy support [5] - The market for traditional Chinese medicinal foods is expected to grow significantly, with a focus on personalized nutrition and health benefits [5] Local Brand Preference - Young Chinese consumers are increasingly favoring local brands over foreign ones, with domestic ice cream brands gaining market share at the expense of international brands like Häagen-Dazs [6] - Local brands are leveraging innovation and flexible marketing strategies to attract the younger generation, reflecting a deeper transformation in the Chinese consumer market [6] Condiment Industry Dynamics - The condiment industry is experiencing a "Matthew Effect," where leading brands like Haitian and Hengshun are becoming stronger, while new product trends focus on health and premiumization [7] - Despite challenges such as raw material price fluctuations, leading brands are maintaining stable growth and improving market share [7] Coconut Water Market - Coconut water is gaining traction as a natural health drink, with market growth expected to reach 7.8 billion yuan by 2024, driven by consumer demand for functional beverages [8] - The market is projected to reach 20 billion yuan by 2029, with supply chain and channel integration being key competitive factors [8] Niche Beverage Segments - The beverage industry is diversifying into niche segments, with brands like Huiyuan Juice launching low-priced birch juice products [9] - The trend towards sugar reduction and functional nutrition is driving the growth of traditional Chinese health water brands, with expectations of market size exceeding 10 billion yuan by 2028 [9] Health-Conscious Beverage Trends - The rise of traditional Chinese health water is attributed to the growing health consciousness among consumers, with market size expected to grow from 0.1 billion yuan in 2018 to 4.5 billion yuan in 2023 [10] - Brands are innovating with unique ingredient combinations to differentiate their products in a crowded market [10] Electrolyte Water Growth - Electrolyte water is becoming a mainstream choice, particularly among health-conscious consumers, with the market expected to reach 23.5 billion yuan by 2025 [13] - The shift from "pleasure consumption" to "functional consumption" is evident, with brands like Yuanqi Forest leading the charge [18] Market Dynamics and Innovations - The beverage market is witnessing a shift towards larger packaging sizes, with 1.5L bottles gaining popularity due to perceived value and cost efficiency [23] - Companies are exploring cross-industry collaborations, such as the partnership between Dairy Farm and Mengniu to launch high-end dairy products [25] Strategic Acquisitions - Ferrero's acquisition of WK Kellogg for $3.1 billion is aimed at expanding its breakfast cereal market presence, complementing its existing chocolate business [20] - This strategic move reflects a broader trend of food companies diversifying their product offerings to capture more market share [20]

证券代码：002644 证券简称：佛慈制药 公告编号：2025-018 兰州佛慈制药股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 兰州佛慈制药股份有限公司（以下简称"公司"）2024 年年度权益分派方案 已获 2025 年 5 月 22 日召开的 2024 年年度股东大会审议通过，现将权益分派实 施事宜公告如下： 3.本次实施的权益分派方案与公司 2024 年年度股东大会审议通过的分配方 案一致。 4.本次实施权益分派方案距离公司 2024 年年度股东大会审议通过的时间未 超过两个月。 二、本次实施的权益分派方案 公司2024年年度权益分派方案为：以公司现有总股本510,657,000股为基数， 向全体股东每 10 股派 0.12 元人民币现金（含税；扣税后，通过深股通持有股份 的香港市场投资者、境外机构（含 QFII、RQFII）以及持有首发前限售股的个人 和证券投资基金每 10 股派 0.108 元；持有首发后限售股、股权激励限售股及无 限售流通股的个人股息红利税实行差别化税率征收，本公司暂不扣缴个人所得税， ...

Market Overview - The Shanghai Composite Index closed at 3346.84 points, slightly above the half-year line, with a change of -0.05% [1] - The total trading volume of A-shares reached 10338.72 billion yuan [1] Stocks Performance - A total of 231 A-shares have surpassed the half-year line, with notable stocks showing significant deviation rates [1] - Stocks with the highest deviation rates include: - Junyao Health: 9.37% - Guangsha Environmental Energy: 8.42% - Longzhou Co., Ltd.: 7.79% [1] - Stocks with lower deviation rates that just crossed the half-year line include: - Wantai Biological Pharmacy: 6.51% - Huatai Securities: 6.40% - Jiayuan Technology: 6.17% [1] Notable Stocks - The top three stocks with the highest daily increase: - Junyao Health: +10.08% - Guangsha Environmental Energy: +9.23% - Longzhou Co., Ltd.: +10.02% [1] - The trading turnover rates for these stocks were also significant, with Guangsha Environmental Energy at 7.92% and Longzhou Co., Ltd. at 8.30% [1] Additional Stocks Data - Other notable stocks with their respective performance: - Huachang Communication: +19.99% with a turnover rate of 12.90% - Huali Technology: +7.44% with a turnover rate of 13.05% [1] - The data indicates a healthy trading environment with several stocks showing strong performance above the half-year line [1]

证券代码：002644 证券简称：佛慈制药 公告编号：2025-017 兰州佛慈制药股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要提示： 1.本次股东大会未出现否决议案的情形； 2.本次股东大会不涉及变更前次股东大会决议。 一、会议召开情况和出席情况 1.会议召开情况 （1）会议召集人：公司董事会； （2）会议主持人：钱双喜先生（董事长单小东先生因公出差，由半数以上 董事共同推举董事、总经理钱双喜先生主持）； （3）现场会议召开时间：2025 年 5 月 22 日（星期四）14：00 （4）现场会议召开地点：甘肃省兰州市兰州新区华山路 2289 号公司五楼会 议室； （5）会议召开方式：本次会议采用现场投票与网络投票表决相结合方式； （6）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 5 月 22 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券 交易所互联网投票系统进行网络投票的时间为 2025 年 5 月 22 日上午 9:15 ...

师事务所 甘肃金城律师事务所 关于 兰州佛慈制药股份有限公司 2024 年年度股东大会 之 法律意见书 二〇二五年五月二十二日 1 / 7 成律师事务所 eng I aw Firm 地址:兰州市七里河区西津西路49号银信大厦20、21层 电话：86-0931-2332066、2332067 传真:86-0931-2302141 网站：www.jclo.com 邮箱：Jclawyer@qq.com Add : 49 XiJing west Road Lanzhou Gansu China Tel：86-0931-2332066、2332067 Fax : 86-0931-2302141 Web : www.jclo.com E-mall : jclawyer@qq.com 地址：兰州市七里河区西津西路49号银信大厦20-21楼 电话：86-0931-2332066、2332067 传真：86-0931-2302141 网站 : www.jclo.com 电子邮箱 : jclawyer@qq.com 甘肃金城律师事务所关于兰州佛慈制药股份有限公司 2024 年年度股东大会之法律意见书 致:兰州佛慈制药股份有限公司 ...